Evidence map›Paper›PMID 42382598›Full record

ArticlePhysics and imaging in radiation oncology2026

Comparative treatment planning of photon, proton and carbon ion radiotherapy for sphenoid wing meningiomas.

Sophie Rauh, Maximilian Y Deng, Inga Jessen, Lisa Seidel, Line Hoeltgen, Semi Harrabi, Filipa Baltazar, Thomas Haberer, Andrea Mairani, Klaus Herfarth and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sophie RauhDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Maximilian Y DengDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Inga JessenDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Lisa SeidelDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Line HoeltgenDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Semi HarrabiDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Filipa BaltazarHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Thomas HabererHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Andrea MairaniHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Klaus HerfarthDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Jürgen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Thomas TessonnierHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Laila KönigDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Sphenoid wing meningiomas (SWMs) are located adjacent to critical organs of interest (OOIs) and present challenges for surgery and radiotherapy. Given the favorable overall survival in meningioma patients, preserving quality of life is important. Dose reductions within OOIs may lower adverse events. This study aimed to evaluate potential advantages of particle therapy regarding dose distribution and side effects for SWMs. Materials and methods: Nine patients (eight females, one male; median age at radiotherapy: 55 years) with SWM received proton radiotherapy (PRT, 54 Gy (RBE), 1.8 Gy (RBE) per fraction). Comparative treatment plans were generated for volumetric modulated arc therapy (VMAT, 54 Gy, 1.8 Gy per fraction) and carbon ion radiotherapy (CIRT, 42 Gy (RBE), 3 Gy (RBE) per fraction). Target volumes and OOI dose guidance were maintained. OOI dose-volume parameters, normal tissue complication probabilities (NTCP), and risk ratios of radiation-induced secondary central nervous system (CNS) malignancies were assessed. Results: Compared to VMAT, mean relative brain doses were reduced by -41.5% with PRT, and - 63.8% with CIRT. Particle therapy achieved significant dose sparing of bilateral hippocampi and lenses, and the ipsilateral inner ear. NTCPs indicated lower risks of ipsilateral hearing loss and cataract with particle therapy. The mean estimated risk of radiation-induced secondary malignancies was 1.7 for photons over protons, and 2.7 for photons over carbon ions. Conclusions: For SWMs, particle therapy demonstrated reduced dose exposure to several OOIs, and may lower the risk of side effects compared with VMAT.

Indexed as

Carbon ion radiotherapyNormal tissue complication probabilityProton radiotherapyRadiation-induced CNS malignanciesSphenoid wing meningiomaTreatment plan comparison

Identifiers

PMID42382598
PMCPMC13316092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.